Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer.
Nicole M Engel-NitzMary G JohnsonMichael P JohnsonAshley S Cha-SilvaSamantha K KuroskyXianchen LiuPublished in: Patient preference and adherence (2023)
In this real-world study, >85% of patients started palbociclib at 125 mg/day and 1 in 3 had dose reductions during the follow-up. Patients were generally adherent and persistent with palbociclib. Older age, bone-only disease, and low-income levels were associated with early discontinuation or non-adherence. Further studies are needed to understand the associations of clinical and economic outcomes with palbociclib adherence and persistence.
Keyphrases
- metastatic breast cancer
- epidermal growth factor receptor
- end stage renal disease
- tyrosine kinase
- endothelial cells
- ejection fraction
- advanced non small cell lung cancer
- glycemic control
- newly diagnosed
- chronic kidney disease
- prognostic factors
- type diabetes
- patient reported outcomes
- body composition
- metabolic syndrome
- adipose tissue
- middle aged
- case control
- bone regeneration